Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Title:	Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
Authors:	Ana Strezova; Javier Diez-Domingo; Kamal Al Shawafi; Juan Carlos Tinoco; Meng Shi; Paola Pirrotta; Agnes Mwakingwe-Omari; Michael Adams; Anitta Ahonen; Charles Andrews; Eugene Athan; Jose Fernando Barbagómez; Piero Barbanti; Elisabeth Barberan; Alain Baty; Niklas Bengtsson; Juergen Berger-Roscher; Katarina Berndtsson Blom; Jean Beytout; Loïc Boucher; Céline Boutry; Alain Boye; François Brault; Laurie Breger; Carles Brotons Cuixart; Covadonga Caso; Christine Cerna; Huey Shinn Cheng; Hee Jin Cheong; Eun Ju Choo; Clóvis Cunha; Anthony L Cunningham; Dan Curiac; Benoit Daguzan; Antje Dahmen; Susan Datta; Maria Giuseppina Desole; Emmanuel Di Paolo; Marc Dionne; Petr Dite; Jan Dutz; John Earl; Tamara Eckermann; William Ellison; Jurij Eremenko; Meral Esen; Takashi Eto; Xavier Farrés Fabré; Cecil Farrington; Murdo Ferguson; Pierre André Ferrand; Matthew Finneran; David Francyk; Marshall Freedman; George Freeman; Antônio Tarcísio Freire; Peter Gal; Jean Sebastien Gauthier; Beatrice Gerlach; Wayne Ghesquiere; Iris Gorfinkel; Christine Grigat; Josef Grosskopf; Monika Hamann; Pascal Hanrion; Paul Hartley; Andrew Hastie; Ken Heaton; Agnes Himpel-Boenninghoff; Thomas Horacek; David Shu Cheong Hui; Yieng Huong; Shinn Jang Hwang; Giancarlo Icardi; Gabriele Illies; Junya Irimajiri; Wilson Jacob; Alen Jambrecina; Thiago Junqueira Avelino-Silva; George Kalema; Hyo Youl Kim; Christiane Klein; Uwe Kleinecke; Hans Joachim Koenig; Satu Kokko; Pavel Kosina; Susanna Koski; Pekka Koskinen; Maximilian Kropp; Rie Kuroki; Outi Laajalahti; Pierre Lachance; Jacob Lee; Jin Soo Lee; Peter Levins; Robert Lipetz; Bo Liu; Chiu Shong Liu; Martin Lundvall; Luci Magimaiseelan; Mary Beth Manning; Jukka Markkula; Frederick Martin; Pyrene Martínez Piera; Damien Mcnally; Shelly Mcneil; Guglielmo Migliorino; Beate Moeckesch; Stephan Morscher; Michael Mueller; Abul Kashem Munir; Cláudia Murta De Oliveira; Kenjiro Nakamura; Silvia Narejos Pérez; Yuji Naritomi; Patrice Nault; José Luiz Neto; Concepción Núñez López; Hiroaki Ogata; Åke Olsson; Pauliina Paavola; Dae Won Park; Janice Patrick; Karlis Pauksens; Mercè Pérez Vera; Lauri Peltonen; Georg Plassmann; Airi Poder; Terry Poling; Carol Pretswell; Samir Purnell-Mullick; George Raad; Michael Redmond; Philippe Remaud; Ernie Riffer; Patrick Robert; Alex Rodríguez Badia; Maria Luisa Rodríguez De La Pinta; Lars Rombo; Robert Rosen; Shari Rozen; Dominique Saillard; Bruno Salaun; Johan Sanmartin Berglund; Joachim Sauter; Axel Schaefer; Isabelle Schenkenberger; Juergen Schmidt; Bernhard Schmitt; Christian Schubert; Anne Schuind; Tino Schwarz; Ilkka Seppa; Edmund Kwok Yiu Sha; Gerald Shockey; Sylvia Shoffner; Elina Sirnela-Rif; Tommaso Staniscia; Hirohiko Sueki; Shin Suzuki; Denis Taminau; Guy Tellier; Manuel Terns Riera; Azhar Toma; Nicole Toursarkissian; Mark Turner; Benita Ukkonen; Anna Vilella Morató; Juergen Wachter; Brian Webster; Karl Wilhelm; Jonathan Wilson; Wilfred Yeo; Chong Jen Yu; Toufik Zahaf; Irina Zahharova; Cristiano Zerbini
Publication Year:	2022
Subject Terms:	adjuvanted recombinant zoster vaccine; immune response persistence; long-term efficacy; long-term safety
Description:	Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.
Document Type:	article in journal/newspaper
Language:	unknown
Relation:	http://hdl.handle.net/10779/DRO/DU:22129730.v3
Availability:	http://hdl.handle.net/10779/DRO/DU:22129730.v3; https://figshare.com/articles/journal_contribution/Long-term_Protection_Against_Herpes_Zoster_by_the_Adjuvanted_Recombinant_Zoster_Vaccine_Interim_Efficacy_Immunogenicity_and_Safety_Results_up_to_10_Years_After_Initial_Vaccination/22129730
Rights:	CC BY 4.0
Accession Number:	edsbas.FA9BAF51
Database:	BASE